Preview

Современная ревматология

Расширенный поиск

Ингибиторы фактора некроза опухоли а и риск сердечно-сосудистых осложнений при ревматоидном артрите

https://doi.org/10.14412/1996-7012-2012-760

Полный текст:

Аннотация

Применение ингибиторов фактора некроза опухоли α (ФНОα), которые селективно блокируют важные звенья иммунопатогенеза ревматоидного артрита (РА), является чрезвычайно эффективным и относительно безопасным методом лечения ревматоидного воспаления и может рассматриваться как новое направление в терапии аутоиммунных заболеваний, в основе которых лежит подавление Т- и В-клеточного звена иммунитета. Вместе с тем необходимо проведение проспективных исследований, которые позволят более точно определить значение ФНОα в развитии сердечно-сосудистых катастроф, а его подавления — в профилактике сердечно-сосудистых осложнений у больных РА.

Литература

1. <div><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M.: ГЭОТАР-Медиа, 2010; 678-702.</p><p>Peters M.J., Symmons D.P., McCarey D.W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2010; 69(2): 325-31.</p><p>Meune C., Touze E., Trinquart L. et al. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and metaanalysis. Arch Cardiovasc Dis 2010; 103: 253—61.</p><p>Avina-Zubieta J.A., Thomas J., Sadatsafavi M. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71(9): 1524—9.</p><p>Van Halm V.P., Peters V.P., Voskuyl M.J. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395—400.</p><p>Nielen M.M., van Sijl A.M., Peters M.J. et al. Cardiovascular disease prevalence in a primary care cohort of individuals with inflammatory arthritis, diabetes, and osteoarthritis: a comparative cross-sectional study [abstract]. Arthr Rheum 2010; 62(Suppl 10): 2211.</p><p>Warrington K.J., Kent P.D., Frye R.L. et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthr Res Ther 2005; 7: 984—91.</p><p>Douglas K.M., Pace A.V., Treharne G.J. et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65: 348—53.</p><p>Södergren A., Stegmayr В., Lundberg V. et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007; 66: 263—6.</p><p>Maradit-Kremers H., Crowson C.S., Nicola P. J. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthr Rheum 2005; 52: 402—11.</p><p>Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005; 52: 722—32.</p><p>Aubry M.C., Maradit-Kremers H., Reinalda M.S. et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheum 2007; 34: 937—42.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004; 440 с.</p><p>Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Науч.-практ. ревматол. 2004; 4: 4—9.</p><p>Gazi I.F., Boumpas D.T., Mikhailidis D.P. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheum 2007; 25: 102—11.</p><p>Teir J., Koduri G., Meadows A. et al. Letter to the editor (other). An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. Rheumatology (Oxford) 2008; 47: 1252—4.</p><p>Sattar N., McCarey D.W., Capell H. et al. Eхрlaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957—63.</p><p>Александрова Е.Н., Новиков А.А., Насонов Е.Л. Высокочувствительные методы определения С-реактивного белка (обзор литературы). Клин. лаб диагност 2004; 11: 16—8.</p><p>Van Halm V.P., Nielen M.M., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184—8.</p><p>Holmqvist M.E., Wedren S., Jacobsson L.T. et al. Rapid increase in myocardial infarction risk following diagnosis of RA amongst patients diagnosed between 1995 and 2006. J Int Med 2010; 268: 578—85.</p><p>Goodson N.J., Symmons D.P., Scott D.G. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthr Rheum 2005; 52: 2293—9.</p><p>Poole C.D., Conway P., Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 78—82.</p><p>Jacobsson L.T., Turesson C., Hanson R.L. et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthr Rheum 2001; 44: 1170—6.</p><p>Wallberg-Jonsson S., Johansson H., Ohman M.L. et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheum 1999; 26: 2562—71.</p><p>Rho Y.H., Chung C.P., Oeser A. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthr Rheum 2009; 15(61): 1580—5.</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum 2002; 46: 2010—9.</p><p>Lopez-Longo F.J., Oliver-Minarro D., de la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum 2009; 61: 419—24.</p><p>Solomon D.H., Kremer J., Curtis J.R et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69(11): 1920—5.</p><p>Karlson E.W., Chibnik L.B., Tworoger S.S. et. al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthr Rheum 2009; 60(3): 641—52.</p><p>Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 724—5.</p><p>Ross R Atherosclerosis — an inflammatory disease. Am Heart J 1999; 138: 419—20.</p><p>Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91: 3—6.</p><p>Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 11—22.</p><p>Sattar N., Mclnnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheum 2005; 17: 286—92.</p><p>Tedgui A., Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 11(88): 877—87.</p><p>Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537—45.</p><p>Full L.E., Ruisanchez C., Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthr Res Ther 2009; 11: 217.</p><p>Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121(Suppl 1): 21—31.</p><p>Pasceri V., Yeh E.T. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124—6.</p><p>Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86(2): 515—81.</p><p>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 720 с.</p><p>Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 11; 340 (6): 448—54.</p><p>Woods A., Brull D.J., Humphries S.E. et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21(19): 1574—83.</p><p>Rattazzi M., Puato M., Faggin E. et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21(10): 1787—803.</p><p>Dixon W.G., Symmons D.P. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132—6.</p><p>Kerekes G., Soltesz P., Der H. et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheum 2009; 28: 705—10.</p><p>Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T.R. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthr Rheum 2008; 59: 1821—4.</p><p>Raterman H.G., Han N.M. et al. Rituximab alters the HDL particle from a pro-inflammatory property in good responding rheumatoid arthritis patients. Arthr Rheum 2010; 62(Suppl10): 332.</p><p>Насонов Е.Л., Каратеев Д.Е. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин. фармакол. тер. 2006; 15(1): 55—8.</p><p>Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheum 2006; 18: 289—97.</p><p>Chia S., Qadan M., Newton R. et al. Intra-arterial tumor necrosis factor-α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arteriol Thromb Vasc Biol 2003; 23: 659—65.</p><p>Zimmerman M., Selzman C., Reznikov L.L. et al. Lack of TNF-α attenuates intimal hyperplasia after mouse carotid artery injury. Am J Physiol Reg Integrat Comp Physiol 2002; 283: 505—12.</p><p>Blann A.D., McCollum C.N. Increased levels of tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels tumor necrosis factor. Inflammation 1998; 22: 483—91.</p><p>Elkind M.S., Cheng J., Boden-Albata B. et al. Tumor necrosis factor levels are associated with carotid atherosclerosis. Stroke 2002; 33: 31—8.</p><p>Ridker P.M., Rifai N., Pfefer M. et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149—53.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Jacobsson L.T., Askling J., Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann Rheum Dis 2008; 67 (Suppl II): 183.</p><p>Carmona L., Descalzo M.A., Perez-Pampin E. et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumor necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880—5.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUESTRA study. Arthr Res Ther 2008; 10: 30.</p><p>Greenberg J.D., Kremer J.M., Curtis J.R. et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4): 576—82.</p><p>Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthr Rheum 2006; 55: 531—6.</p><p>Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthr Rheum 2006; 54: 3790—8.</p><p>Wolfe F., Michaud K. The risk of myocardial infarction and pharmacologic and non-pharmacologic myocardial infarction predictictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthr Rheum 2008; 58: 2612—21.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum 2007; 56: 2905—12.</p><p>Al-Aly Z., Pan H., Zeringue A. et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011; 157(1): 10—8.</p><p>Sing G. Combination TNF-inhibitor-methotrexate therapy is superior to methotrexate monotherapy in reducing the risk of acute myocardial infarction in patients with rheumatoid arthritis. Arthr Rheum 2007; 56 (Suppl II): 535.</p><p>Ljung L., Simard J.F., Jacobsson L. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthr Rheum 2012; 64(1): 42—52.</p><p>Barnabe C., Martin B.J., Ghali W. A. Systematic review and meta-analysis: antitumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthr Care Res (Hoboken) 2011; 63(4): 522—9.</p><p>Giles J.T., Fernandes V., Lima J.A. et al. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthr Res Ther 2005; 7(5): 195—207.</p><p>Davis J.M., Knutson K.L., Strausbauch M.A. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthr Rheum 2011; 63(6): 1497—506.</p><p>Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594—602.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133—40.</p><p>Danila M.I., Patkara N.M., Curtisa J.R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheum 2008; 20: 327—33.</p><p>Kwon H.J. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807—11.</p><p>Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthr Rheum 2006; 54: 2807—16.</p><p>Westhovens R., Yocum D., Han J. et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthr Rheum 2006; 54: 1075—86.</p><p>St Clair E.W., van der Heijde D.M., Smolen J.S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004; 50: 3432—43.</p><p>Schiff M.H., Burmester G.R., Kent J.D. et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889—94.</p><p>Feltelius N., Fored C.M., Blomqvist P. et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64: 246—52.</p><p>Redfield M.M., Rodeheffer R.J., Jacobsen S.J. et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109(25): 3176—81.</p><p>Harney S.M., Timperley J., Daly C. et al. Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(1): 136.</p><p>Provan S.A., Angel K., Odegard S. et al. http://www.ncbi.nlm.nih.gov/pubmed?term=Atar%20D%5BAuthor%5D&amp;cauthor=true&amp;ca uthor_uid=18573197 The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthr Res Ther 2008; 10(3): R70.</p><p>Crowson C.S., Myasoedova E., Davis J.M. et al. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Arthr Care Res (Hoboken) 2011; 63(5): 729—34.</p><p>Peters M.J., Welsh P., McInnes I.B. et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69(7): 1281—5.</p><p>Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305—11.</p><p>Curtis J.R., Kramer J.M., Martin C. et al. Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 2007; 46: 1688—93.</p><p>Listing J., Strangfeld A., Kekow J. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthr Rheum 2008; 58: 667—77.</p><p>Lazzerini P.E., Acampa M., Hammoud M. et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheum 2008; 35(10): 1958—65.</p><p>Del Porto F., Lagana В., Lai S. et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007; 46: 1111—5.</p><p>Sidiropoulus P.I., Siakka P., Pagonidis K. et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheum 2009; 38: 6—10.</p><p>Gonzales-Juataney C., Liorca J., Garcia-Porrua et al. Effect of anti- tumor necrosis factor-alpha therapy on the progression of sub-clinical atherosclerosis in severe rheumatoid arthritis. Arhr Rheum 2006; 55: 150—3.</p><p>Bathon J., Wasko M.-C., Kirkham В. et al. Golimumab and cardiovascular disease: carotid artery ultrasound evaluation and cardiovascular adverse events. Ann Rheum Dis 2010; 69 (Suppl 3): 464.</p><p>Hurliman D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alfa treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184—7.</p><p>Gonzales-Gay M.A., De Matis J.M., Gonzalez-Juataney C. et al. Anti-tumor necrosis factors-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheum 2006; 24: 83—6.</p><p>Gonzalez-Juanatey С., Testa A., Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-alfa antibody. Arthr Rheum 2004; 51: 447—50.</p><p>Irace C., Mancuso G., Fiaschi E. et al. Effect of anti TNF-α therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177: 113—8.</p><p>Van Doornum S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1428—32.</p><p>Angel K., Provan S.A., Agewall S. et al. TNF-alpha antagonists reduce arterial stiffness in patients with rheumatoid arthritis and related arthropaties: a controlled study. Ann Rheum Dis 2008; 67(Suppl II): 160.</p><p>Cypiene A., Laucevicius A., Venalis A. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 2007; 50: 119—22.</p><p>Maki-Petaja K.M., Hall F.C., Booth A.D. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114: 1185—92.</p><p>Клинические рекомендации европейского общества кардиологов. М., 2008; 186 с.</p><p>Kerekes G., Soltesz P., Szucs G. et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011; 13(3): 147—52.</p><p>Del Rincon I.D., Williams K., Stern M.P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr Rheum 2001; 44: 2737—45.</p><p>Dessein P.H., Joffe B.I., Veller M.G. et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheum 2005; 32: 435—42.</p><p>Nielen M.J., van Halm V.P., Numohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum 2003; 48: 344—50.</p><p>Navab M., Berliner J.A., Subbanagounder G. et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arteriol Thromb Vasc Biol 2001; 21: 481—8.</p><p>McMahon M., Grossman J., FitzGerald J. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthr Rheum 2006; 54(8): 2541—9.</p><p>Sattar N., Choi E. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460—9.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч.-практ. ревматол. 2007; 5: 4—10.</p><p>Schimmel E.K., Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exper Rheum 2009; 27: 446—51.</p><p>Pollono E.N., Lopez-Olivo M.A., Lopez J.A. et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheum 2010; 29(9): 947—55.</p><p>Daien C.I., Duny Y., Barnetche T. et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann. Rheum Dis 2012; 71(6): 862—8.</p><p>Vis M., Nurmohamed M.T., Wolbink G. et al. Short term effects on the lipid profile in in patients with rheumatoid arthritis. J Rheum 2005; 32: 252—5.</p><p>Popa C., Radstake T., Netea M.G., et al. Influence of anti-tumor necrosis factor-alfa therapy on cardiovascular risk factors in patients with active rheumatoid. Ann Rheum Dis 2005; 64: 303—5.</p><p>Popa C., Radstake T., Netea M.G. et al. Long- term anti TNF alfa therapy effect on lipoprotein concentrations in patients with active rheumatoid arthritis (abstract). Arthr Rheum 2006; 54: 9—11.</p><p>Spanakis E., Sidiropouls P., Papadakis J. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritis treated with Infliximab. Arthr Rheum 2006; 33: 12.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis 2006; 33: 4921—3.</p><p>Cauza E., Cauza K., Hanusch-Ensener U. et al. Intravenosus anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 1004—7.</p><p>Seriolio В., Paolino S., Sulli A. et al. Effect of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069: 414—9.</p><p>Peters M.J.L., Vis M., Van Halm V.P. et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66(7): 958—61.</p><p>Saiki O., Takao R., Naruse Y. et al. Infliximab but not methotrexate induces extrahigh levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Reumatol 2007; 34(10): 1997—2004.</p><p>Dominguez H., Storgaard H., Rask-Madsen C. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517—25.</p><p>Huvers F. C., Popa C., Netea M. et al. Improved insulin sensitivity by anti-TNF-α antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007; 66: 558—9.</p><p>Stavropoulos-Kalinoglou A., Metsios G.S., Koutedakis Y. et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66(10): 1316—21.</p><p>Marcora S.M., Chester K.R., Mittal G. et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84(6): 1463—72.</p><p>Metsios G.S., Stavropoulos-Kalinoglou A., Douglas K.M. et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007; 46(12): 1824—7.</p><p>Roubenoff R., Roubenoff R.A., Cannon J.G. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93(6): 2379—86.</p><p>Seriolo В., Ferrone C., Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheum 2008; 35(2): 355—7.</p><p>Seriolo В., Paolino S., Ferrone C. et al. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheum 2007; 26(10): 1799—800.</p><p>Oguz F.M., Oguz A., Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 2007; 62(4): 218—22.</p></div><br />


Для цитирования:


Попкова Т.В., Новикова Д.С., Насонов Е.Л. Ингибиторы фактора некроза опухоли а и риск сердечно-сосудистых осложнений при ревматоидном артрите. Современная ревматология. 2012;6(4):30-39. https://doi.org/10.14412/1996-7012-2012-760

For citation:


Popkova T.V., Novikova D.S., Nasonov E.L. Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis. Modern Rheumatology Journal. 2012;6(4):30-39. (In Russ.) https://doi.org/10.14412/1996-7012-2012-760

Просмотров: 940


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)